Corporate Presentation Monte Rosa Corporate Presentation – December 2024 6.1 MB Presentations San Antonio Breast Cancer Symposium – Selective Targeting of CDK2 Using Molecular Glue Degraders for the Treatment of HR-Positive/HER2-Negative Breast Cancer 997.1 KB 7th Annual TPD & Induced Proximity Summit – Molecular Glue Degraders: From the Bench to the Clinic 3 MB 7th Annual TPD & Induced Proximity Summit – Rational Design of Selective CDK2 and Cyclin E1 MGDs 2.5 MB Selective Targeting of Cyclin E1 Using Molecular Glue Degraders in CCNE1 Amplified Solid Malignancies 13.3 MB 6th Annual Inflammasome Summit – Exploring Novel Modalities: Disabling the NLRP3 Inflammasome with a NEK7 Molecular Glue Degrader 2.8 MB Trends in Immunology - VAV1 as a Putative Therapeutic Target in Autoimmune and Chronic Inflammatory Diseases 1.2 MB EULAR 2024 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Reduces Joint Inflammation and Autoantibody Production in a Collagen-Induced Arthritis Autoimmune Disease Model 3.1 MB DDW 2024 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a T-cell Transfer Mediated Colitis Model Concomitant with Reduced Calprotectin Expression 1.2 MB AACR 2024 – The GSPT1 Molecular Glue Degrader MRT-2359 Is Active against Prostate Cancer 1.9 MB Molecular Glue Drug Development Summit January 2024 – Accelerating Molecular Glue Discovery Through AI/ML & Computation 8.6 MB Keystone Symposia January 2024 – Teaching CRBN New Tricks 6.3 MB ACR 2023 – A VAV1-Directed Molecular Glue Degrader, MRT-6160, Reduces Joint Inflammation in a Collagen-Induced Arthritis Autoimmune Disease Model 8.5 MB Monte Rosa Company Call Presentation - October 17 2023 1.8 MB AACR 2023 - Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction 4.3 MB AACR 2023 - Discovery of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for MYC-driven cancers 4.4 MB MRT-2359 KOL Webinar, October 24, 2022 4.5 MB 34th EORTC-NCI-AACR Symposium 4.1 MB 5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359 5.1 MB 5th Annual TPD Summit - AI Applications for Molecular Glue Degraders 9.2 MB American Association for Cancer Research Annual Meeting, April 8-13, 2022 1 MB 2nd Annual TPD Europe Summit Presentation 3.9 MB 4th Annual Targeted Protein Degradation Summit Presentation 4.8 MB AACR-NCI-EORTC Late Breaking Presentation 2.1 MB European Protein Degradation Congress 2021 Presentation 3.8 MB
San Antonio Breast Cancer Symposium – Selective Targeting of CDK2 Using Molecular Glue Degraders for the Treatment of HR-Positive/HER2-Negative Breast Cancer 997.1 KB
San Antonio Breast Cancer Symposium – Selective Targeting of CDK2 Using Molecular Glue Degraders for the Treatment of HR-Positive/HER2-Negative Breast Cancer 997.1 KB
7th Annual TPD & Induced Proximity Summit – Molecular Glue Degraders: From the Bench to the Clinic 3 MB
7th Annual TPD & Induced Proximity Summit – Molecular Glue Degraders: From the Bench to the Clinic 3 MB
7th Annual TPD & Induced Proximity Summit – Rational Design of Selective CDK2 and Cyclin E1 MGDs 2.5 MB
7th Annual TPD & Induced Proximity Summit – Rational Design of Selective CDK2 and Cyclin E1 MGDs 2.5 MB
Selective Targeting of Cyclin E1 Using Molecular Glue Degraders in CCNE1 Amplified Solid Malignancies 13.3 MB
Selective Targeting of Cyclin E1 Using Molecular Glue Degraders in CCNE1 Amplified Solid Malignancies 13.3 MB
6th Annual Inflammasome Summit – Exploring Novel Modalities: Disabling the NLRP3 Inflammasome with a NEK7 Molecular Glue Degrader 2.8 MB
6th Annual Inflammasome Summit – Exploring Novel Modalities: Disabling the NLRP3 Inflammasome with a NEK7 Molecular Glue Degrader 2.8 MB
Trends in Immunology - VAV1 as a Putative Therapeutic Target in Autoimmune and Chronic Inflammatory Diseases 1.2 MB
Trends in Immunology - VAV1 as a Putative Therapeutic Target in Autoimmune and Chronic Inflammatory Diseases 1.2 MB
EULAR 2024 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Reduces Joint Inflammation and Autoantibody Production in a Collagen-Induced Arthritis Autoimmune Disease Model 3.1 MB
EULAR 2024 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Reduces Joint Inflammation and Autoantibody Production in a Collagen-Induced Arthritis Autoimmune Disease Model 3.1 MB
DDW 2024 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a T-cell Transfer Mediated Colitis Model Concomitant with Reduced Calprotectin Expression 1.2 MB
DDW 2024 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a T-cell Transfer Mediated Colitis Model Concomitant with Reduced Calprotectin Expression 1.2 MB
Molecular Glue Drug Development Summit January 2024 – Accelerating Molecular Glue Discovery Through AI/ML & Computation 8.6 MB
Molecular Glue Drug Development Summit January 2024 – Accelerating Molecular Glue Discovery Through AI/ML & Computation 8.6 MB
ACR 2023 – A VAV1-Directed Molecular Glue Degrader, MRT-6160, Reduces Joint Inflammation in a Collagen-Induced Arthritis Autoimmune Disease Model 8.5 MB
ACR 2023 – A VAV1-Directed Molecular Glue Degrader, MRT-6160, Reduces Joint Inflammation in a Collagen-Induced Arthritis Autoimmune Disease Model 8.5 MB
AACR 2023 - Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction 4.3 MB
AACR 2023 - Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction 4.3 MB
AACR 2023 - Discovery of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for MYC-driven cancers 4.4 MB
AACR 2023 - Discovery of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for MYC-driven cancers 4.4 MB